Icon

CAMPTOSAR (nda020571)- (40MG/2ML (20MG/ML),100MG/5ML (20MG/ML),300MG/15ML (20MG/ML))

IRINOTECAN HYDROCHLORIDE PFIZER INC
40MG/2ML (20MG/ML),100MG/5ML (20MG/ML),300MG/15ML (20MG/ML)
Yes No
2020-Nov-01 Expired
None None
None No
CAMPTOSAR is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
19 0 10
Total Other Developers 5
Drugs with Suitability No
40MG/2ML (20MG/ML) ** ** - - -
100MG/5ML (20MG/ML) ** ** - - -
300MG/15ML (20MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 10
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ********* **** *** ********* **** ***, *** *********** **** *. **** ****** **** ***** ********* ******, ******* ****, ******** (**) *****, ****** ****** (***) ***
****** ******* ******* ********* *** *** *********** *-** ***** **, ********, ******** ****, ********* (***) ***
****** ******* ***** ******* ******** ******* ******* *********** **** **.*, *******, ******* ******** ****, ******* ***** *******, ******* ******, ****** ******, *********, ******* ******, ***** (***) ***
****** ******* ****** ******* ******* *************** **., ***. (******* **** ****) *********** ** ******* ****, ******** & ************* *********** ****,, ***********, ******* ******, ***** (***) ***
****** ***** ************ ********** **** ********* *********** ************ **, **********, ***** ****** *****, ******* (***) ***
****** **** ***** ****** **** ************** (******) **., ***. *********** **.***-*, ****** ******, ******** ****-**** ****, ******, ****** ******, ***** (***) ***
****** ****** **** ******* *************** **** *********** *** ********* **, ********, ****** ****, *********** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.